Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. 1988

E Steiner, and L Bertilsson, and J Säwe, and I Bertling, and F Sjöqvist
Department of Clinical Pharmacology, Karolinska Institute, Huddinge University Hospital, Sweden.

The metabolic ratios (MRs) between debrisoquin and 4-hydroxydebrisoquin in urine after a single oral dose of 10 mg debrisoquin were bimodally distributed in 757 healthy, white Swedish volunteers. Forty-one subjects (5.4%) had an MR greater than 12.6 and were classified as slow debrisoquin hydroxylators. The MR was reproducible in urine stored at +8 degrees C for 1 week and at -20 degrees C over a period of 5 years. Collection intervals of 6 or 12 hours gave the same MR. Intraindividual repeatability of the debrisoquin phenotyping test was established in 37 subjects examined twice at least 2 weeks apart. The calculated frequency of the single allele that is believed to control deficient debrisoquin hydroxylation is similar among white Swedish people, as among other white groups examined so far; however, it is significantly different from the frequency in certain Oriental groups. Detailed comparisons of the prevalence of slow debrisoquin hydroxylation in different ethnic groups are not possible due to shortcomings in current epidemiologic techniques used (small materials, the location of the antimode distinguishing rapid and slow hydroxylators unknown, and family studies missing).

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D003647 Debrisoquin An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism. Debrisoquine,Tendor
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

E Steiner, and L Bertilsson, and J Säwe, and I Bertling, and F Sjöqvist
July 1989, Clinical pharmacology and therapeutics,
E Steiner, and L Bertilsson, and J Säwe, and I Bertling, and F Sjöqvist
December 1985, Clinical pharmacology and therapeutics,
E Steiner, and L Bertilsson, and J Säwe, and I Bertling, and F Sjöqvist
May 1989, Clinical pharmacology and therapeutics,
E Steiner, and L Bertilsson, and J Säwe, and I Bertling, and F Sjöqvist
October 1985, Clinical pharmacology and therapeutics,
E Steiner, and L Bertilsson, and J Säwe, and I Bertling, and F Sjöqvist
May 1990, Presse medicale (Paris, France : 1983),
E Steiner, and L Bertilsson, and J Säwe, and I Bertling, and F Sjöqvist
March 1987, Clinical pharmacology and therapeutics,
E Steiner, and L Bertilsson, and J Säwe, and I Bertling, and F Sjöqvist
January 1992, Clinical pharmacology and therapeutics,
E Steiner, and L Bertilsson, and J Säwe, and I Bertling, and F Sjöqvist
September 1986, Orvosi hetilap,
E Steiner, and L Bertilsson, and J Säwe, and I Bertling, and F Sjöqvist
April 1994, Clinical pharmacology and therapeutics,
E Steiner, and L Bertilsson, and J Säwe, and I Bertling, and F Sjöqvist
November 1979, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!